Abstract: The present disclosure describes simple, stable, and scalable antiviral therapeutic agent compositions that transform short-acting antiviral (e.g., anti-HIV) therapeutic agents that would otherwise require daily short-acting oral administration into long-acting injectable forms that lasts for many weeks per administration. A mixture of water-soluble and water-insoluble antiviral therapeutic agents can be present in the long-acting and drug-combination composition.

Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.

Abstract: The present disclosure describes an injectable aqueous dispersion, including an aqueous solvent, and a chemotherapeutic agent composition dispersed in the aqueous solvent to provide the injectable aqueous dispersion. The chemotherapeutic agent composition includes a combination of chemotherapeutic agents selected from: gemcitabine and paclitaxel; and venetoclax and zanubrutinib. The chemotherapeutic agent composition further includes one or more compatibilizers comprising a lipid (e.g., a lipid excipient), a lipid conjugate, or a combination thereof. The chemotherapeutic agents of the chemotherapeutic agent composition exhibit a synergistic chemotherapeutic effect.

Abstract: Described herein are combination pharmaceutical compositions including a combination of hydrophilic and hydrophobic therapeutic agents (i.e., drugs) that are assembled together with excipients under specific conditions, forming a homogeneous pharmaceutical powder with unified repetitive multi-drug motif (MDM) structure. Unlike currently available drug combination powders, which are amorphous, the combination pharmaceutical compositions (e.g.

Abstract: Lipid nanoparticles expressing metal ions and methods for using the compositions for magnetic resonance imaging.

Abstract: Provided are multi-drug lipid nanoparticles that stably incorporate multiple small molecule drugs with divergent hydrophobic and water solubility characteristics and related methods of making and using the same, The disclosed compositions and methods provide for enhanced stability of lipid nanoparticle drug formulations that can reliably provide drugs addressing different mechanistic targets with prolonged presence in the body for more efficacious treatment and avoidance of single drug resistance.

Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.

Abstract: Compositions, devices, and methods for treating infections.

Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.

Abstract: Provided are multi-drug lipid nanoparticles that stably incorporate multiple small molecule drugs with divergent hydrophobic and water solubility characteristics and related methods of making and using the same, The disclosed compositions and methods provide for enhanced stability of lipid nanoparticle drug formulations that can reliably provide drugs addressing different mechanistic targets with prolonged presence in the body for more efficacious treatment and avoidance of single drug resistance.

Abstract: Drug-polymer complexes, drug-polymer particles, drug-polymer particle formulations, and methods for making and using the complexes, particles, and formulations. The drug-polymer complex is prepared by a melt-quench process in which a combination of a drug and a polymer are heated to or above the melting point of the drug and polymer and then cooled.

Abstract: The present invention relates to lipid-associated indocyanine green particles for enhanced functional high-resolution near-infrared fluorescence medical imaging of lymphatic vessels, lymph nodes, lymphatic abnormalities, tumors, and inflammation.

Abstract: The present application discloses devices and methods for delivering a therapeutic compound to the olfactory epithelium of an animal or human. The device having one or more channels for imparting a circumferential and axial velocity to the discharged fluid, and an outlet that discharges an aerosol spray having a circumferential and axial velocity as it enters the nasal cavity of a user. The device is designed to displace the air in the upper nasal cavity in order to specifically deposit a therapeutic agent on the olfactory epithelium while minimizing pressure and discomfort experienced by the user.

Abstract: The present application discloses devices and methods for delivering a therapeutic compound to the olfactory epithelium of an animal or human. The device having one or more channels for imparting a circumferential and axial velocity to the discharged fluid, and an outlet that discharges an aerosol spray having a circumferential and axial velocity as it enters the nasal cavity of a user. The device is designed to displace the air in the upper nasal cavity in order to specifically deposit a therapeutic agent on the olfactory epithelium while minimizing pressure and discomfort experienced by the user.

Abstract: Lipid nanoparticles expressing metal ions and methods for using the compositions for magnetic resonance imaging.

Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.

Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.

Abstract: The present invention relates to lipid-associated indocyanine green particles for enhanced functional high-resolution near-infrared fluorescence medical imaging of lymphatic vessels, lymph nodes, lymphatic abnormalities, tumors, and inflammation.

Abstract: The present application discloses devices and methods for delivering a therapeutic compound to the olfactory epithelium of an animal or human. The device having one or more channels for imparting a circumferential and axial velocity to the discharged fluid, and an outlet that discharges an aerosol spray having a circumferential and axial velocity as it enters the nasal cavity of a user. The device is designed to displace the air in the upper nasal cavity in order to specifically deposit a therapeutic agent on the olfactory epithelium while minimizing pressure and discomfort experienced by the user.

Abstract: Compositions, devices, and methods for treating infections.